| Dr Jason Christopher Bell, DO | |
|
1904 Pine St Ste 200, Abilene, TX 79601-2450 | |
| (325) 670-5570 | |
| (325) 670-4024 |
| Full Name | Dr Jason Christopher Bell |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 16 Years |
| Location | 1904 Pine St Ste 200, Abilene, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033376983 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hendrick Medical Center | Abilene, TX | Hospital |
| Brownwood Regional Medical Center | Brownwood, TX | Hospital |
| Haskell Memorial Hospital | Haskell, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hendrick Provider Network | 9739162181 | 231 |
News Archive
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.
Veiovis, a leading global healthcare company in the medical travel industry, announces its new partnership with Medtral New Zealand, a provider of first-rate healthcare experiences in New Zealand. The partnership further expands Veiovis' network of medical travel options across Asia and the Pacific, and provides patients with access to New Zealand's finest private hospitals and specialists.
There is strong evidence that inflammation promotes obesity-associated type 2 diabetes and diabetes complications. However, clinical trials with anti-inflammatory drugs have only been modestly effective for treating Type 2 diabetes. A new fingerprint of inflammation that may be able to predict which patients with obesity may also develop type 2 diabetes has been identified by Boston University School of Medicine researchers.
MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
A widely used combination of two common medications may cause unexpected increases in blood glucose levels, according to a study conducted at the Stanford University School of Medicine, Vanderbilt University and Harvard Medical School. Researchers were surprised at the finding because neither of the two drugs - one, an antidepressant marketed as Paxil, and the other, a cholesterol-lowering medication called Pravachol - has a similar effect alone.
› Verified 8 days ago
| Entity Name | Utmb Faculty Group Practice |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241146 PECOS PAC ID: 3375456734 Enrollment ID: O20031112000438 |
News Archive
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.
Veiovis, a leading global healthcare company in the medical travel industry, announces its new partnership with Medtral New Zealand, a provider of first-rate healthcare experiences in New Zealand. The partnership further expands Veiovis' network of medical travel options across Asia and the Pacific, and provides patients with access to New Zealand's finest private hospitals and specialists.
There is strong evidence that inflammation promotes obesity-associated type 2 diabetes and diabetes complications. However, clinical trials with anti-inflammatory drugs have only been modestly effective for treating Type 2 diabetes. A new fingerprint of inflammation that may be able to predict which patients with obesity may also develop type 2 diabetes has been identified by Boston University School of Medicine researchers.
MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
A widely used combination of two common medications may cause unexpected increases in blood glucose levels, according to a study conducted at the Stanford University School of Medicine, Vanderbilt University and Harvard Medical School. Researchers were surprised at the finding because neither of the two drugs - one, an antidepressant marketed as Paxil, and the other, a cholesterol-lowering medication called Pravachol - has a similar effect alone.
› Verified 8 days ago
| Entity Name | Hendrick Provider Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396961322 PECOS PAC ID: 9739162181 Enrollment ID: O20040609001047 |
News Archive
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.
Veiovis, a leading global healthcare company in the medical travel industry, announces its new partnership with Medtral New Zealand, a provider of first-rate healthcare experiences in New Zealand. The partnership further expands Veiovis' network of medical travel options across Asia and the Pacific, and provides patients with access to New Zealand's finest private hospitals and specialists.
There is strong evidence that inflammation promotes obesity-associated type 2 diabetes and diabetes complications. However, clinical trials with anti-inflammatory drugs have only been modestly effective for treating Type 2 diabetes. A new fingerprint of inflammation that may be able to predict which patients with obesity may also develop type 2 diabetes has been identified by Boston University School of Medicine researchers.
MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
A widely used combination of two common medications may cause unexpected increases in blood glucose levels, according to a study conducted at the Stanford University School of Medicine, Vanderbilt University and Harvard Medical School. Researchers were surprised at the finding because neither of the two drugs - one, an antidepressant marketed as Paxil, and the other, a cholesterol-lowering medication called Pravachol - has a similar effect alone.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason Christopher Bell, DO Po Box 1198, Abilene, TX 79604-1198 Ph: (325) 670-4372 | Dr Jason Christopher Bell, DO 1904 Pine St Ste 200, Abilene, TX 79601-2450 Ph: (325) 670-5570 |
News Archive
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.
Veiovis, a leading global healthcare company in the medical travel industry, announces its new partnership with Medtral New Zealand, a provider of first-rate healthcare experiences in New Zealand. The partnership further expands Veiovis' network of medical travel options across Asia and the Pacific, and provides patients with access to New Zealand's finest private hospitals and specialists.
There is strong evidence that inflammation promotes obesity-associated type 2 diabetes and diabetes complications. However, clinical trials with anti-inflammatory drugs have only been modestly effective for treating Type 2 diabetes. A new fingerprint of inflammation that may be able to predict which patients with obesity may also develop type 2 diabetes has been identified by Boston University School of Medicine researchers.
MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
A widely used combination of two common medications may cause unexpected increases in blood glucose levels, according to a study conducted at the Stanford University School of Medicine, Vanderbilt University and Harvard Medical School. Researchers were surprised at the finding because neither of the two drugs - one, an antidepressant marketed as Paxil, and the other, a cholesterol-lowering medication called Pravachol - has a similar effect alone.
› Verified 8 days ago
Lindsey Pittillo, FNP-BC Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1957 Antilley Rd, Abilene, TX 79606 Phone: 325-692-0188 | |
Dr. Ralphie Alberto Rosario Feliciano, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1665 Antilley Rd Ste 260, Abilene, TX 79606 Phone: 325-793-5223 Fax: 325-793-5236 | |
Dr. Amelia Lorenzo, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 4225 Woods Pl, Abilene, TX 79602 Phone: 325-695-3252 Fax: 325-695-3414 | |
Mustapha Ali Khalife, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2000 Pine St, Abilene, TX 79601 Phone: 253-670-6340 Fax: 903-877-7825 | |
Dr. Ralph F. Heaven, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1100 N 19th St, Suite 1a, Abilene, TX 79601 Phone: 325-672-4368 Fax: 325-672-3108 | |
Mrs. Amelia Y Yeh, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 3210 Antilley Rd, Abilene, TX 79606 Phone: 325-795-1600 Fax: 325-692-4780 | |
Dr. Farley Berry Graden Neasman Iii, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 6200 Regional Plz Ste 1675, Abilene, TX 79606 Phone: 325-428-4790 Fax: 325-428-5855 |